9:25 am Chairperson’s Opening Remarks

Analyzing How to Marry Your Linker-Payload to Your Target For a Maximized Therapeutic Index

9:30 am The Vital Triad of ADC Design: Target, Indication & Payload

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics


  • Reviewing how the selection of an ADC target requires consideration of the potential clinical indications and the mechanistic properties of available linker payloads
  • Assessing how the availability of novel differentiated linker-payloads provides an opportunity to calibrate potential clinical success against validated clinical benchmarks
  • Presenting case study examples to demonstrate integration of target selection, clinical indication options and payload MoA

10:00 am Tubutecan Platform: Technology-enabled Payload Solutions Targeting Topoisomerase-I

  • Annette Vogl Director, Biology & Translational Research, Tubulis GmbH


  • Understand how Tubulis’ P5-conjugation technology enabled rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies
  • Topoisomerase-I-inhibitors have become a promising payload class for ADCs in solid tumors. Tubutecans are a novel linker-payload platform for ADCs enabling the efficient and steady delivery of the TOPO-I-targeting payloads to the malignant cells
  • Evaluate how the implementation of an in vitro screen for on-target/off-tumor effects aids in designing the optimal combination of linker-payload and DAR matched with target properties

10:30 am
Speed Networking Break


This session is an opportunity to connect with peers working in target selection and hold indepth conversations with some of the brightest minds working in the ADC field to establish meaningful and lasting relationships.

11:30 am Talk Details TBC

  • Jamie Rich Director, Antibody- Drug Conjugate Technology & Therapeutic Development, Zymeworks

12:00 pm Building an ADC: What are the Key Characteristics You Need to Select For With Target in Mind


  • Examining the key characteristics that influenced the matching of the specific payload to the specific target
  • Providing a case study of a METxMET Bispecific ADC for NSCLC
  • Exploring how the METxMET ADC could potentially be effective in a larger population of lung cancer patients than MET blockers

12:30 pm
Lunch & Networking

Express Yourself – Examining the Importance of Expression Profile

1:30 pm Targeted Cancer Therapy for Patients With 17p Deletion

  • Anikó Pálfi Director, Biochemistry & Cell Biology, Heidelberg Pharma Research GmbH


  • Discussing Del(17p) as a potential platform-wide predictive biomarker for amanitin based ADCs
  • Highlighting superior efficacy of amanitin based ADCs in cancer models with 17p loss
  • Outlining the expedited clinical development of HDP-101 for Del(17p) patients

2:00 pm Panel Discussion – Examining to What Extent Target Expression is a Good Biomarker for Clinical Success

  • Anikó Pálfi Director, Biochemistry & Cell Biology, Heidelberg Pharma Research GmbH
  • Seema Kantak Senior Vice President, Biotherapeutics, Exelixis


  • How are targets best used as biomarkers?
  • What are the biomarkers we could have to better understand the target?
  • Does expected target expression translate into clinical efficacy?
  • What screening approaches exist to improve patient selection and ultimately clinical outcomes?

2:40 pm
Afternoon Break

3:10 pm Panel Discussion – Thinking Strategically About What Targets You Select

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics
  • Annette Vogl Director, Biology & Translational Research, Tubulis GmbH
  • Yu Shen Director, Oncology Discovery, AbbVie


  • Understanding where your target choice and ADC fits into the ADC and wider oncology landscape?
  • How do you differentiate yourself through using improved linker-payload technologies on previously validated targets?
  • Balancing risk in your pipeline through your target choice
  • Novel targets or previously validated targets?
  • Discussing the role of future HER2 ADCs

3:55 pm Chairperson’s Closing Remarks

4:00 pm Scientific Poster Session


While the formal presentations of Day One come to an end, the learning doesn’t stop as we enter the Scientific Poster Session. This will serve as the perfect opportunity to showcase your recent work to your peers and allow you to learn and share insights in a relaxed atmosphere.

5:00 pm End of Conference Day One